Recro Pharma (NASDAQ:REPH) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Recro Pharma (NASDAQ:REPH) from a buy rating to a hold rating in a research note released on Thursday, Zacks.com reports.

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

Shares of REPH stock opened at $2.05 on Thursday. The stock has a 50 day simple moving average of $2.17 and a 200 day simple moving average of $2.46. The company has a current ratio of 14.29, a quick ratio of 12.81 and a debt-to-equity ratio of 3.40. Recro Pharma has a 1 year low of $1.49 and a 1 year high of $5.29. The stock has a market cap of $95.56 million, a P/E ratio of -2.66 and a beta of 1.16.

Recro Pharma (NASDAQ:REPH) last released its earnings results on Monday, August 9th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.14. Analysts forecast that Recro Pharma will post -0.3 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in Recro Pharma by 21.0% during the first quarter. JPMorgan Chase & Co. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $84,000 after purchasing an additional 5,212 shares during the last quarter. Barclays PLC lifted its stake in shares of Recro Pharma by 159.0% in the 1st quarter. Barclays PLC now owns 16,203 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 9,946 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Recro Pharma in the 1st quarter valued at $28,000. Hourglass Capital LLC lifted its stake in shares of Recro Pharma by 100.0% in the 2nd quarter. Hourglass Capital LLC now owns 40,000 shares of the specialty pharmaceutical company’s stock valued at $92,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Frontier Wealth Management LLC lifted its stake in shares of Recro Pharma by 48.0% in the 2nd quarter. Frontier Wealth Management LLC now owns 72,705 shares of the specialty pharmaceutical company’s stock valued at $2,980,000 after acquiring an additional 23,593 shares during the last quarter. Hedge funds and other institutional investors own 68.57% of the company’s stock.

About Recro Pharma

Recro Pharma, Inc is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products.

Featured Article: Learning About the VIX – Volatility Index

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.